Digital and virtual nutrition coaching services support people using GLP-1 medicines when appetite and meal tolerance change during treatment
GLP-1, the endogenous agonist of GLP-1R, is predominantly synthesized in enteroendocrine cells of the distal small intestine and secreted in the blood when food enters the duodenum [4, 5]
Early studies suggest that Retatrutide could achieve greater weight reduction and broader metabolic benefits at lower relative exposure compared with Tirzepatide, although phase 3 trials are ongoing to confirm these findings
Some practitioners step down from 2.4mg to 1.7mg for a month, then to 1.0mg for a month, then to 0.5mg for a month before stopping completely
De Angelis M, Rizzello CG, Fasano A, et al